A pilot study of neoadjuvant paclitaxel and radiation with correlative molecular studies in stage II/III breast cancer.

A. Chakravarthy, B. Nicholson, M. Kelley, D. Beauchamp, D. Johnson, M. Frexes-Steed, J. Simpson, Yu Shyr, J. Pietenpol

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A commonly used approach to the management of locally advanced breast cancer currently involves neoadjuvant chemotherapy, followed by surgery and radiation. Earlier neoadjuvant regimens had utilized doxorubicin, making concurrent treatment with radiation less desirable given dose-limiting normal tissue toxicities. With the development of paclitaxel, we can now reconsider the use of concurrent chemoradiation in the treatment of breast cancer. Although paclitaxel is a known radiation sensitizer, its precise mechanism of action is still unclear. One of its proposed mechanisms is that it binds tubulin and induces an M-phase arrest. As cells in M-phase are very sensitive to radiation, it thereby increases radiation sensitivity. The ability to predict tumor response for individual patients would allow us to tailor subsequent therapy for the individual patient. This study is designed to evaluate if paclitaxel's effects on the cell cycle of an individual patient can predict the responsiveness of that patient's tumor to paclitaxel and radiation. Patients will be treated with 3 cycles of paclitaxel followed by concurrent paclitaxel and radiation prior to definitive surgery.

Original languageEnglish
Pages (from-to)68-71
Number of pages4
JournalClinical breast cancer
Volume1
Issue number1
DOIs
Publication statusPublished - 2000 Jan 1

Fingerprint

Paclitaxel
Radiation
Breast Neoplasms
Cell Division
Radiation-Sensitizing Agents
Radiation Tolerance
Tubulin
Doxorubicin
Neoplasms
Cell Cycle
Therapeutics
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Chakravarthy, A., Nicholson, B., Kelley, M., Beauchamp, D., Johnson, D., Frexes-Steed, M., ... Pietenpol, J. (2000). A pilot study of neoadjuvant paclitaxel and radiation with correlative molecular studies in stage II/III breast cancer. Clinical breast cancer, 1(1), 68-71. https://doi.org/10.3816/CBC.2000.n.007
Chakravarthy, A. ; Nicholson, B. ; Kelley, M. ; Beauchamp, D. ; Johnson, D. ; Frexes-Steed, M. ; Simpson, J. ; Shyr, Yu ; Pietenpol, J. / A pilot study of neoadjuvant paclitaxel and radiation with correlative molecular studies in stage II/III breast cancer. In: Clinical breast cancer. 2000 ; Vol. 1, No. 1. pp. 68-71.
@article{014a4c50510245ddb8c6934cab8415ea,
title = "A pilot study of neoadjuvant paclitaxel and radiation with correlative molecular studies in stage II/III breast cancer.",
abstract = "A commonly used approach to the management of locally advanced breast cancer currently involves neoadjuvant chemotherapy, followed by surgery and radiation. Earlier neoadjuvant regimens had utilized doxorubicin, making concurrent treatment with radiation less desirable given dose-limiting normal tissue toxicities. With the development of paclitaxel, we can now reconsider the use of concurrent chemoradiation in the treatment of breast cancer. Although paclitaxel is a known radiation sensitizer, its precise mechanism of action is still unclear. One of its proposed mechanisms is that it binds tubulin and induces an M-phase arrest. As cells in M-phase are very sensitive to radiation, it thereby increases radiation sensitivity. The ability to predict tumor response for individual patients would allow us to tailor subsequent therapy for the individual patient. This study is designed to evaluate if paclitaxel's effects on the cell cycle of an individual patient can predict the responsiveness of that patient's tumor to paclitaxel and radiation. Patients will be treated with 3 cycles of paclitaxel followed by concurrent paclitaxel and radiation prior to definitive surgery.",
author = "A. Chakravarthy and B. Nicholson and M. Kelley and D. Beauchamp and D. Johnson and M. Frexes-Steed and J. Simpson and Yu Shyr and J. Pietenpol",
year = "2000",
month = "1",
day = "1",
doi = "10.3816/CBC.2000.n.007",
language = "English",
volume = "1",
pages = "68--71",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "1",

}

Chakravarthy, A, Nicholson, B, Kelley, M, Beauchamp, D, Johnson, D, Frexes-Steed, M, Simpson, J, Shyr, Y & Pietenpol, J 2000, 'A pilot study of neoadjuvant paclitaxel and radiation with correlative molecular studies in stage II/III breast cancer.', Clinical breast cancer, vol. 1, no. 1, pp. 68-71. https://doi.org/10.3816/CBC.2000.n.007

A pilot study of neoadjuvant paclitaxel and radiation with correlative molecular studies in stage II/III breast cancer. / Chakravarthy, A.; Nicholson, B.; Kelley, M.; Beauchamp, D.; Johnson, D.; Frexes-Steed, M.; Simpson, J.; Shyr, Yu; Pietenpol, J.

In: Clinical breast cancer, Vol. 1, No. 1, 01.01.2000, p. 68-71.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A pilot study of neoadjuvant paclitaxel and radiation with correlative molecular studies in stage II/III breast cancer.

AU - Chakravarthy, A.

AU - Nicholson, B.

AU - Kelley, M.

AU - Beauchamp, D.

AU - Johnson, D.

AU - Frexes-Steed, M.

AU - Simpson, J.

AU - Shyr, Yu

AU - Pietenpol, J.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - A commonly used approach to the management of locally advanced breast cancer currently involves neoadjuvant chemotherapy, followed by surgery and radiation. Earlier neoadjuvant regimens had utilized doxorubicin, making concurrent treatment with radiation less desirable given dose-limiting normal tissue toxicities. With the development of paclitaxel, we can now reconsider the use of concurrent chemoradiation in the treatment of breast cancer. Although paclitaxel is a known radiation sensitizer, its precise mechanism of action is still unclear. One of its proposed mechanisms is that it binds tubulin and induces an M-phase arrest. As cells in M-phase are very sensitive to radiation, it thereby increases radiation sensitivity. The ability to predict tumor response for individual patients would allow us to tailor subsequent therapy for the individual patient. This study is designed to evaluate if paclitaxel's effects on the cell cycle of an individual patient can predict the responsiveness of that patient's tumor to paclitaxel and radiation. Patients will be treated with 3 cycles of paclitaxel followed by concurrent paclitaxel and radiation prior to definitive surgery.

AB - A commonly used approach to the management of locally advanced breast cancer currently involves neoadjuvant chemotherapy, followed by surgery and radiation. Earlier neoadjuvant regimens had utilized doxorubicin, making concurrent treatment with radiation less desirable given dose-limiting normal tissue toxicities. With the development of paclitaxel, we can now reconsider the use of concurrent chemoradiation in the treatment of breast cancer. Although paclitaxel is a known radiation sensitizer, its precise mechanism of action is still unclear. One of its proposed mechanisms is that it binds tubulin and induces an M-phase arrest. As cells in M-phase are very sensitive to radiation, it thereby increases radiation sensitivity. The ability to predict tumor response for individual patients would allow us to tailor subsequent therapy for the individual patient. This study is designed to evaluate if paclitaxel's effects on the cell cycle of an individual patient can predict the responsiveness of that patient's tumor to paclitaxel and radiation. Patients will be treated with 3 cycles of paclitaxel followed by concurrent paclitaxel and radiation prior to definitive surgery.

UR - http://www.scopus.com/inward/record.url?scp=0034174860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034174860&partnerID=8YFLogxK

U2 - 10.3816/CBC.2000.n.007

DO - 10.3816/CBC.2000.n.007

M3 - Article

C2 - 11899393

AN - SCOPUS:0034174860

VL - 1

SP - 68

EP - 71

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 1

ER -